Literature DB >> 17471175

Role of neutrophil elastase in LTB4-induced neutrophil transmigration in vivo assessed with a specific inhibitor and neutrophil elastase deficient mice.

R E Young1, M-B Voisin, S Wang, J Dangerfield, S Nourshargh.   

Abstract

BACKGROUND AND
PURPOSE: The serine protease neutrophil elastase (NE) appears to regulate inflammatory responses at multiple levels but its role in leukocyte transmigration in vivo remains unclear. The present study aimed to address this issue by using both an NE inhibitor (ONO-5046) and NE deficient (NE(-/-)) mice. EXPERIMENTAL APPROACH: A number of inflammatory mediators (LTB(4), KC and PAF) were investigated in vitro for their ability to stimulate the release and the surface expression of NE by neutrophils. In addition, the role of NE in leukocyte migration elicited by topical LTB(4) was investigated in vivo in mouse cremasteric venules as observed by intravital microscopy. KEY
RESULTS: Amongst the mediators tested in vitro, LTB(4) was found to be a highly potent and efficacious inducer of NE cell surface expression on murine neutrophils. Furthermore, in wild-type mice (WT), LTB(4)-induced leukocyte transmigration was reduced by intravenous ONO-5046 (66% inhibition), an effect that appeared to occur at the level of the perivascular basement membrane. Interestingly, LTB(4)-induced responses were normal in NE(-/-) mice and, while ONO-5046 had no inhibitory effect in these animals, the broad-spectrum serine protease inhibitor aprotinin suppressed leukocyte transmigration in both WT and NE(-/-) mice. CONCLUSIONS AND IMPLICATIONS: The findings demonstrate the potent ability of LTB(4) to induce cell-surface expression of NE and provide evidence for the involvement of NE in LTB(4)-induced neutrophil transmigration in vivo. The results also suggest the existence of compensatory mechanisms in NE(-/-) mice, highlighting the added value of investigating pharmacological blockers in parallel with genetic deletion.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17471175      PMCID: PMC2013993          DOI: 10.1038/sj.bjp.0707267

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  42 in total

1.  Impaired immunity and enhanced resistance to endotoxin in the absence of neutrophil elastase and cathepsin G.

Authors:  J Tkalcevic; M Novelli; M Phylactides; J P Iredale; A W Segal; J Roes
Journal:  Immunity       Date:  2000-02       Impact factor: 31.745

Review 2.  Migration of leukocytes through the vessel wall and beyond.

Authors:  Rashmi Yadav; Karen Y Larbi; Rebecca E Young; Sussan Nourshargh
Journal:  Thromb Haemost       Date:  2003-10       Impact factor: 5.249

3.  Cardioprotective effects of the serine protease inhibitor aprotinin after regional ischemia and reperfusion on the beating heart.

Authors:  Diethard Pruefer; Ute Buerke; Markus Khalil; Manfred Dahm; Harald Darius; Hellmut Oelert; Michael Buerke
Journal:  J Thorac Cardiovasc Surg       Date:  2002-11       Impact factor: 5.209

4.  Polymorphonuclear leukocyte elastase in patients with stroke.

Authors:  N Vila; M Elena; R Deulofeu; A Chamorro
Journal:  Acta Neurol Scand       Date:  1999-12       Impact factor: 3.209

5.  Neutrophils from MMP-9- or neutrophil elastase-deficient mice show no defect in transendothelial migration under flow in vitro.

Authors:  Jennifer R Allport; Yaw-Chyn Lim; J Michael Shipley; Robert M Senior; Steven D Shapiro; Norihisa Matsuyoshi; Dietmar Vestweber; Francis W Luscinskas
Journal:  J Leukoc Biol       Date:  2002-05       Impact factor: 4.962

6.  Protection against acute lung injury by intravenous or intratracheal pretreatment with EPI-HNE-4, a new potent neutrophil elastase inhibitor.

Authors:  Christophe Delacourt; Sabine Hérigault; Christophe Delclaux; Alain Poncin; Micheline Levame; Alain Harf; François Saudubray; Chantal Lafuma
Journal:  Am J Respir Cell Mol Biol       Date:  2002-03       Impact factor: 6.914

7.  Deficiency in neutrophil elastase does not impair neutrophil recruitment to inflamed sites.

Authors:  Tim O Hirche; Jefferey J Atkinson; Scott Bahr; Abderrazzaq Belaaouaj
Journal:  Am J Respir Cell Mol Biol       Date:  2003-10-17       Impact factor: 6.914

8.  Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes.

Authors:  A W Ford-Hutchinson; M A Bray; M V Doig; M E Shipley; M J Smith
Journal:  Nature       Date:  1980-07-17       Impact factor: 49.962

9.  Detection of collagen type II and proteoglycans in the synovial fluids of patients diagnosed with non-infectious knee joint synovitis indicates early damage to the articular cartilage matrix.

Authors:  K A Elsaid; G D Jay; C O Chichester
Journal:  Osteoarthritis Cartilage       Date:  2003-09       Impact factor: 6.576

10.  Neutrophil elastase (NE)-deficient mice demonstrate a nonredundant role for NE in neutrophil migration, generation of proinflammatory mediators, and phagocytosis in response to zymosan particles in vivo.

Authors:  Rebecca E Young; Richard D Thompson; Karen Y Larbi; Mylinh La; Clare E Roberts; Steven D Shapiro; Mauro Perretti; Sussan Nourshargh
Journal:  J Immunol       Date:  2004-04-01       Impact factor: 5.422

View more
  34 in total

1.  Inhibition of neutrophil-mediated production of reactive oxygen species (ROS) by endothelial cells is not impaired in anti-neutrophil cytoplasmic autoantibodies (ANCA)-associated vasculitis patients.

Authors:  F Al Laham; A-I Kälsch; L Heinrich; R Birck; C G M Kallenberg; P Heeringa; B Yard
Journal:  Clin Exp Immunol       Date:  2010-05-07       Impact factor: 4.330

2.  Proteinase 3 contributes to transendothelial migration of NB1-positive neutrophils.

Authors:  Christopher J Kuckleburg; Sarah B Tilkens; Sentot Santoso; Peter J Newman
Journal:  J Immunol       Date:  2012-01-20       Impact factor: 5.422

Review 3.  Neutrophils cascading their way to inflammation.

Authors:  Christian D Sadik; Nancy D Kim; Andrew D Luster
Journal:  Trends Immunol       Date:  2011-08-11       Impact factor: 16.687

Review 4.  Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases.

Authors:  Brice Korkmaz; Marshall S Horwitz; Dieter E Jenne; Francis Gauthier
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 5.  Neutrophil migration under normal and sepsis conditions.

Authors:  Yelena V Lerman; Minsoo Kim
Journal:  Cardiovasc Hematol Disord Drug Targets       Date:  2015

6.  Role of leukotriene A4 hydrolase aminopeptidase in the pathogenesis of emphysema.

Authors:  Mikell Paige; Kan Wang; Marie Burdick; Sunhye Park; Josiah Cha; Erin Jeffery; Nicholas Sherman; Y Michael Shim
Journal:  J Immunol       Date:  2014-04-25       Impact factor: 5.422

7.  Neutrophil elastase mediates acute pathogenesis and is a determinant of long-term behavioral recovery after traumatic injury to the immature brain.

Authors:  Bridgette D Semple; Alpa Trivedi; Kayleen Gimlin; Linda J Noble-Haeusslein
Journal:  Neurobiol Dis       Date:  2014-12-09       Impact factor: 5.996

8.  Venular basement membranes ubiquitously express matrix protein low-expression regions: characterization in multiple tissues and remodeling during inflammation.

Authors:  Mathieu-Benoît Voisin; Doris Pröbstl; Sussan Nourshargh
Journal:  Am J Pathol       Date:  2009-12-11       Impact factor: 4.307

9.  Cathepsin G Controls Arterial But Not Venular Myeloid Cell Recruitment.

Authors:  Almudena Ortega-Gomez; Melanie Salvermoser; Jan Rossaint; Robert Pick; Janine Brauner; Patricia Lemnitzer; Jessica Tilgner; Renske J de Jong; Remco T A Megens; Janina Jamasbi; Yvonne Döring; Christine T Pham; Christoph Scheiermann; Wolfgang Siess; Maik Drechsler; Christian Weber; Jochen Grommes; Alexander Zarbock; Barbara Walzog; Oliver Soehnlein
Journal:  Circulation       Date:  2016-09-22       Impact factor: 29.690

10.  Monocytes and neutrophils exhibit both distinct and common mechanisms in penetrating the vascular basement membrane in vivo.

Authors:  Mathieu-Benoît Voisin; Abigail Woodfin; Sussan Nourshargh
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-06-04       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.